VIDEO: IDH inhibitor treatment sequence for AML a 'hot topic of discussion' at ASH
In this video, Akriti Jain, MD, discusses whether patients with acute myeloid leukemia with IDH mutations should be treated with IDH inhibitors up front compared to venetoclaxcontaining regimens.
Randomized trials are needed in this area to determine the optimal treatment sequence, Jain said, however a study of note comparing AML regimens at this year's ASH Annual Meeting and Exposition. The real-world study compared initial treatment with azacitadine and ivosidenib to initial treatment with venetoclax and ivosidenib.
"Initial treatment with azacitadine and ivosidenib led to much improved rates,” Jain, a leukemia and myeloid disorders physician at the Cleveland Clinic, said.
“They achieved CR faster, they had longer eventfree survival compared to patients treated with venetoclax," Jain said.
However, the study received some criticism since patients treated with venetoclax did not receive the treatment for more than 11 days per cycle, Jain said.
"This potentially impacted the regimen's efficacy and being able to achieve complete remission rates," Jain said.
Reference:
- Smith BD, et al A Comparison of Acute Myeloid Leukemia (AML) Regimens: Hypomethylating Agents Combined with Ivosidenib or Venetoclax in Newly Diagnosed Patients with IDH1 Mutations: A Real-World Evidence Study. Presented at: ASH Annual Meeting and Exposition, Dec. 9-12, 2023; San Diego.
Collapse
Healio Interviews
Read more about